Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy

A multicenter collaborative study

Hiroi Kaku, Seisuke Kumagai, Hiroki Onoue, Anna Takada, Tadahiro Shoji, Fumiharu Miura, Akira Yoshizaki, Shinya Sato, Junzo Kigawa, Tsutomu Arai, Shinpei Tsunoda, Eiichirou Tominaga, Daisuke Aoki, Toru Sugiyama

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Paclitaxel/carboplatin chemotherapy for cancer (TC therapy) exhibits neurotoxicity and causes peripheral neuropathy at a high frequency, which is difficult to cope with. In this study, we investigated the efficacy of Goshajinkigan, a traditional Japanese herbal medicine, for TC therapy-induced peripheral neuropathy. The subjects included in our study were patients with ovarian or endometrial cancer who underwent TC therapy and developed peripheral neuropathy. The patients were randomly divided into Group A, comprising of 14 patients (vitamin B12 treatment), and Group B, comprising of 15 patients (vitamin B12 + Goshajinkigan treatment). The observation period was 6 weeks following treatment initiation, and the evaluation items were as follows: i) the current perception threshold (CPT value) of the peripheral nerve, ii) visual analogue scale for numbness, iii) National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade of neurotoxicity, and iv) a questionnaire on the subjective symptoms of peripheral neuropathy (functional assessment of cancer therapy-taxane). These were compared between the groups and no significant differences were noted in any item. However, CTCAE grade 3 neurotoxicity developed in 2 patients (14.3%) after 6 weeks of administration in Group A, whereas no neurotoxicity was observed in Group B. When the change in the frequency of abnormal CPT ratio at 6 weeks of administration from that before treatment was compared between the groups, the frequency of abnormal value was significantly lower in Group B than in Group A (p<0.05). This suggests that Goshajinkigan inhibits the progression of peripheral neuropathy.

Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalExperimental and Therapeutic Medicine
Volume3
Issue number1
DOIs
Publication statusPublished - 2012 Jan

Fingerprint

Carboplatin
Peripheral Nervous System Diseases
Paclitaxel
Multicenter Studies
Therapeutics
Vitamin B 12
Hypesthesia
National Cancer Institute (U.S.)
gosha-jinki-gan
Herbal Medicine
Endometrial Neoplasms
Visual Analog Scale
Peripheral Nerves
Terminology
Ovarian Neoplasms
Neoplasms
Observation
Drug Therapy

Keywords

  • Goshajinkigan
  • Gynecological cancer
  • Japanese herbal medicine
  • Kampo drugs
  • Neurotoxicity
  • Paclitaxel
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Cite this

Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy : A multicenter collaborative study. / Kaku, Hiroi; Kumagai, Seisuke; Onoue, Hiroki; Takada, Anna; Shoji, Tadahiro; Miura, Fumiharu; Yoshizaki, Akira; Sato, Shinya; Kigawa, Junzo; Arai, Tsutomu; Tsunoda, Shinpei; Tominaga, Eiichirou; Aoki, Daisuke; Sugiyama, Toru.

In: Experimental and Therapeutic Medicine, Vol. 3, No. 1, 01.2012, p. 60-65.

Research output: Contribution to journalArticle

Kaku, Hiroi ; Kumagai, Seisuke ; Onoue, Hiroki ; Takada, Anna ; Shoji, Tadahiro ; Miura, Fumiharu ; Yoshizaki, Akira ; Sato, Shinya ; Kigawa, Junzo ; Arai, Tsutomu ; Tsunoda, Shinpei ; Tominaga, Eiichirou ; Aoki, Daisuke ; Sugiyama, Toru. / Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy : A multicenter collaborative study. In: Experimental and Therapeutic Medicine. 2012 ; Vol. 3, No. 1. pp. 60-65.
@article{6dbe98cf191e46e19b693b77b91128c1,
title = "Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study",
abstract = "Paclitaxel/carboplatin chemotherapy for cancer (TC therapy) exhibits neurotoxicity and causes peripheral neuropathy at a high frequency, which is difficult to cope with. In this study, we investigated the efficacy of Goshajinkigan, a traditional Japanese herbal medicine, for TC therapy-induced peripheral neuropathy. The subjects included in our study were patients with ovarian or endometrial cancer who underwent TC therapy and developed peripheral neuropathy. The patients were randomly divided into Group A, comprising of 14 patients (vitamin B12 treatment), and Group B, comprising of 15 patients (vitamin B12 + Goshajinkigan treatment). The observation period was 6 weeks following treatment initiation, and the evaluation items were as follows: i) the current perception threshold (CPT value) of the peripheral nerve, ii) visual analogue scale for numbness, iii) National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade of neurotoxicity, and iv) a questionnaire on the subjective symptoms of peripheral neuropathy (functional assessment of cancer therapy-taxane). These were compared between the groups and no significant differences were noted in any item. However, CTCAE grade 3 neurotoxicity developed in 2 patients (14.3{\%}) after 6 weeks of administration in Group A, whereas no neurotoxicity was observed in Group B. When the change in the frequency of abnormal CPT ratio at 6 weeks of administration from that before treatment was compared between the groups, the frequency of abnormal value was significantly lower in Group B than in Group A (p<0.05). This suggests that Goshajinkigan inhibits the progression of peripheral neuropathy.",
keywords = "Goshajinkigan, Gynecological cancer, Japanese herbal medicine, Kampo drugs, Neurotoxicity, Paclitaxel, Peripheral neuropathy",
author = "Hiroi Kaku and Seisuke Kumagai and Hiroki Onoue and Anna Takada and Tadahiro Shoji and Fumiharu Miura and Akira Yoshizaki and Shinya Sato and Junzo Kigawa and Tsutomu Arai and Shinpei Tsunoda and Eiichirou Tominaga and Daisuke Aoki and Toru Sugiyama",
year = "2012",
month = "1",
doi = "10.3892/etm.2011.375",
language = "English",
volume = "3",
pages = "60--65",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy

T2 - A multicenter collaborative study

AU - Kaku, Hiroi

AU - Kumagai, Seisuke

AU - Onoue, Hiroki

AU - Takada, Anna

AU - Shoji, Tadahiro

AU - Miura, Fumiharu

AU - Yoshizaki, Akira

AU - Sato, Shinya

AU - Kigawa, Junzo

AU - Arai, Tsutomu

AU - Tsunoda, Shinpei

AU - Tominaga, Eiichirou

AU - Aoki, Daisuke

AU - Sugiyama, Toru

PY - 2012/1

Y1 - 2012/1

N2 - Paclitaxel/carboplatin chemotherapy for cancer (TC therapy) exhibits neurotoxicity and causes peripheral neuropathy at a high frequency, which is difficult to cope with. In this study, we investigated the efficacy of Goshajinkigan, a traditional Japanese herbal medicine, for TC therapy-induced peripheral neuropathy. The subjects included in our study were patients with ovarian or endometrial cancer who underwent TC therapy and developed peripheral neuropathy. The patients were randomly divided into Group A, comprising of 14 patients (vitamin B12 treatment), and Group B, comprising of 15 patients (vitamin B12 + Goshajinkigan treatment). The observation period was 6 weeks following treatment initiation, and the evaluation items were as follows: i) the current perception threshold (CPT value) of the peripheral nerve, ii) visual analogue scale for numbness, iii) National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade of neurotoxicity, and iv) a questionnaire on the subjective symptoms of peripheral neuropathy (functional assessment of cancer therapy-taxane). These were compared between the groups and no significant differences were noted in any item. However, CTCAE grade 3 neurotoxicity developed in 2 patients (14.3%) after 6 weeks of administration in Group A, whereas no neurotoxicity was observed in Group B. When the change in the frequency of abnormal CPT ratio at 6 weeks of administration from that before treatment was compared between the groups, the frequency of abnormal value was significantly lower in Group B than in Group A (p<0.05). This suggests that Goshajinkigan inhibits the progression of peripheral neuropathy.

AB - Paclitaxel/carboplatin chemotherapy for cancer (TC therapy) exhibits neurotoxicity and causes peripheral neuropathy at a high frequency, which is difficult to cope with. In this study, we investigated the efficacy of Goshajinkigan, a traditional Japanese herbal medicine, for TC therapy-induced peripheral neuropathy. The subjects included in our study were patients with ovarian or endometrial cancer who underwent TC therapy and developed peripheral neuropathy. The patients were randomly divided into Group A, comprising of 14 patients (vitamin B12 treatment), and Group B, comprising of 15 patients (vitamin B12 + Goshajinkigan treatment). The observation period was 6 weeks following treatment initiation, and the evaluation items were as follows: i) the current perception threshold (CPT value) of the peripheral nerve, ii) visual analogue scale for numbness, iii) National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 grade of neurotoxicity, and iv) a questionnaire on the subjective symptoms of peripheral neuropathy (functional assessment of cancer therapy-taxane). These were compared between the groups and no significant differences were noted in any item. However, CTCAE grade 3 neurotoxicity developed in 2 patients (14.3%) after 6 weeks of administration in Group A, whereas no neurotoxicity was observed in Group B. When the change in the frequency of abnormal CPT ratio at 6 weeks of administration from that before treatment was compared between the groups, the frequency of abnormal value was significantly lower in Group B than in Group A (p<0.05). This suggests that Goshajinkigan inhibits the progression of peripheral neuropathy.

KW - Goshajinkigan

KW - Gynecological cancer

KW - Japanese herbal medicine

KW - Kampo drugs

KW - Neurotoxicity

KW - Paclitaxel

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84855400940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855400940&partnerID=8YFLogxK

U2 - 10.3892/etm.2011.375

DO - 10.3892/etm.2011.375

M3 - Article

VL - 3

SP - 60

EP - 65

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 1

ER -